oral sel. PDE2A phosphodiesterase inhibitor

for cognition, target engagement in brain

from HTS, SBDD, and FEP claculations

J. Med. Chem., Oct. 26, 2020

Janssen Pharmaceutica NV, Beerse, BE

Structure of compound 46

“compound 46” (Janssen oral selective brain-penetrant PDE2A phosphodiesterase inhibitor)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: